Chronic Otitis Media with Effusion: Diagnosis, Treatment and Ventilation Tube Decision

Otitis media with effusion (OME) is sterile or low-pathogen fluid in the middle ear without the classic signs of acute bacterial infection (pain, fever, otorrhoea, bulging red drum). Duration: acute <3 weeks; subacute 3 weeks-3 months; chronic (OME) >3 months.

Common in children — WHO data: every child has at least one OME episode by age 7; 80% resolve spontaneously within 3 months, 20-30% become chronic. Peak incidence 2-7 years — immature Eustachian tube anatomy (short, wide, horizontal — pathogens and nasopharyngeal content reach middle ear easily).

Pathophysiology — Eustachian tube dysfunction (ETD) is central: (1) Mechanical obstruction (adenoid hypertrophy, nasal polyps, allergic mucosal oedema); (2) Functional dysfunction (orifice does not fully open on swallowing — tubal dilator muscle weakness); (3) Mucosal inflammation (URI, smoke, GERD). ETD generates middle-ear negative pressure, then transudate is secreted.

Fluid evolution: initially serous (watery, few cells), later mucoid (sticky, glue ear — chronic), and fibrous in long-standing (organised). Fluid character affects treatment — mucoid is resistant to medication, strengthens tube indication.

Microbiome: OME fluid usually sterile (classical culture negative), but modern PCR detects low-density bacterial DNA (H. influenzae, S. pneumoniae, M. catarrhalis — biofilm-resistant to antibiotic). Hence limited efficacy of medical antibiotics.

Risk factors — strong: age 2-7, daycare (cross-infection), passive smoking (strongest environmental — Eustachian mucosa irritation), formula feeding (vs breast — immunity, antibody difference), male sex (slight predominance), Down syndrome (craniofacial + immune), cleft palate (tubal dilator anatomy), allergic rhinitis, GERD, immunodeficiency, family history.

Seasonal: winter-spring peak (viral URI season), summer minimum. Similar Turkish epidemiology.

Adult OME — special note: rare in adults; unilateral adult OME mandates nasopharyngeal cancer screening (in Turkey not as endemic as Far East but seen — Mediterranean and Black Sea coasts higher incidence). Nasopharyngeal endoscopy + biopsy + neck node examination + MRI. We expand on the clinical framework in our otology and hearing centre.

Paediatric OME is usually "silent" — no pain, no fever, no acute features. Families therefore notice late or it is detected on school-age screening.

Early findings (family observation): loud TV/tablet, asking to repeat, no response when called, attention loss when turned (affected ear side), balance issues (rare — when fluid dense), reduced social interaction, falling school performance.

Speech development: chronic bilateral OME before 18 months can cause speech delay. High-frequency consonants (s, f, t, k) lost → unclear speech, comprehension difficulty, vocabulary reduction. Untreated OME at 2-3 years risks permanent speech-language disorder.

School performance: chronic OME in school-age screening linked to attention problems, reading difficulty, back-of-class underperformance. Early treatment restores academic outcome.

Adult OME findings: unilateral ear fullness, hearing loss (autophony — own voice sounds different), ETD sensation (cannot equalise on flight), tinnitus (middle-ear pressure changes — low-frequency). Unilateral adult OME → nasopharyngeal cancer screening!

Otoscopy findings: (1) thickened/dull drum (lost lustre); (2) air-fluid level (most pathognomonic — straight line above haziness); (3) air bubbles; (4) colour change (yellow, amber, blue-grey — chronic); (5) retraction (especially pars flaccida); (6) reduced mobility (on pneumatic otoscopy).

Pneumatic otoscopy: air puff to drum — normal moves, OME immobile. High specificity. Core paediatric skill.

Tympanometry (impedance audiometry): middle-ear pressure-volume curve. Type A (normal — peak around 0 mmH2O), Type B (flat, no peak — pathognomonic for effusion), Type C (negative-pressure peak — ETD, pre-OME — ETD without effusion). Objective gold standard.

Pure-tone audiometry (>4 years): conductive loss (air conduction 20-40 dB, normal bone conduction, air-bone gap +). Paediatric <4 years — behavioural or visual reinforcement audiometry (VRA).

Otoacoustic emission (DPOAE/TEOAE): newborn + infant screening — DPOAE absent when OME (middle-ear fluid blocks emission). Supportive.

ABR: infant — when VRA not possible. OME raises ABR thresholds.

Adult additional workup: nasal endoscopy (adenoid remnant, sinus disease, polyp), nasopharyngeal examination (cancer suspicion — biopsy if needed), allergy testing (IgE, prick), GERD assessment (24-hour pH or empiric PPI trial).

OME treatment is stepped — watch → medical → surgical. AAO-HNS (American Academy of Otolaryngology-Head and Neck Surgery) 2016 guideline is the main reference; TKBB has similar recommendations.

Watchful waiting — first 3 months: ~50% spontaneous resolution, especially after viral URI. Except risk groups (Down syndrome, cleft palate, speech delay), initial watch is appropriate. Inform family — symptoms, follow-up, alarm features (acute worsening — bacterial complication).

Medical treatment — limited evidence: (1) Antibiotics: AAO-HNS 2016 NOT recommended generally — short-term benefit (2-4 weeks) but no long-term, resistance risk. Only in acute exacerbation (AOM added — pain, fever, discharge). (2) Nasal corticosteroid: useful if allergic component (with allergic rhinitis — mometasone, fluticasone 4-6 weeks trial). (3) Antihistamine: if allergic; ineffective if non-allergic. (4) Mucolytic (acetylcysteine): weak evidence, AAO-HNS not recommended. (5) Topical/systemic decongestant: short-term (5 days) may help, long-term rebound. (6) Eustachian tube exercises: Valsalva (older children + adults), Politzer (clinic), Otovent balloon (>4-5 years, at home — inflate balloon through nose); comfort + tubal opening helper, limited scientific evidence.

Surgical indications — ventilation tube (tympanostomy tube, grommet): AAO-HNS 2016 clear criteria. (1) 3+ months bilateral OME + ≥25 dB hearing loss (in both or worse ear); (2) Unilateral 6+ months OME + hearing/speech impact; (3) Speech delay + OME; (4) Recurrent AOM (3+/year) + persistent effusion between; (5) Risk groups: Down syndrome, cleft palate (early tube regardless of duration); (6) Atelectatic drum (advanced retraction, cholesteatoma risk).

Ventilation tube procedure: general anaesthesia (child) or local (adult, cooperative). Microscope-guided myringotomy (drum incision, anterior-inferior quadrant) → middle-ear fluid aspiration → tube insertion. 10-15 minutes, usually day-case. Types: short-term grommet (titanium, fluoroplastic — 6-18 months, falls out spontaneously); long-term T-tube (silicone — 2-3+ years, recurrent need).

Adenoidectomy — combined with tube: >4 years + significant adenoid hypertrophy (nasopharyngeal obstruction, snoring, mouth breathing) — tube + adenoidectomy combined. <4 years tube only (adenoid still small). Adenoidectomy reduces recurrence by 30-50% — fewer new effusions after tube extrusion.

Tube complications (mostly minor): tube blockage (wax, blood — drops; replace if needed), early extrusion (within 4-6 weeks — may need new tube), persistent perforation (failure of drum closure after tube extrusion — <2%; recurrent OME history higher), myringosclerosis (drum calcification — cosmetic, no functional impact), cholesteatoma (very rare — <1%), otorrhoea (through tube — water entry, bathing/swimming).

Postop care: dry ear (first 2 weeks — special plug during bathing + swimming; afterwards specific advice — some children always need plugs, others only for pool/sea), antibiotic ear drops (first week — infection prevention), follow-up (4-6 weeks, 3 months, 6 months, yearly — tube position, hearing test, drum status).

Adult OME management: differs from children — nasopharyngeal screening mandatory (especially unilateral). Eustachian tube dilation (modern technique — balloon Eustachian tuboplasty, endoscopic) useful in selected cases. Treat allergy + GERD + sinus disease. Ventilation tube less commonly in adults — addressing underlying ETD takes priority.

Hearing aid option: if tube cannot be applied in critical speech development period (e.g. very young infant, family refusal) or residual loss after tube, bone-conduction or conventional hearing aid usable — most cases tube remains primary solution. Step-by-step details: hearing loss page.

OME generally has good prognosis — full recovery typical with right-time treatment. But neglected chronic disease may cause irreversible changes.

Late complications — structural: (1) Drum atelectasis — long-term negative pressure causes drum adherence (retraction); pars flaccida and posterosuperior quadrant common; if progresses, cholesteatoma risk; (2) Cholesteatoma — deep retraction into middle ear, epithelial accumulation, bone erosion — surgical treatment (tympanomastoidectomy) needed; (3) Permanent sensorineural hearing loss — chronic inflammation spreads to inner ear (rare); (4) Adhesive otitis media — middle ear fills with fibrous tissue, ossicular fixation, permanent conductive loss.

Late complications — functional: speech-language disorder (especially <18 months + long OME), academic delay, social-behavioural problems (hearing inadequacy), balance issues (vestibular — rare).

Post-tube prognosis: 70-80% of patients have no recurrence after tube extrusion, hearing normalises, speech catches up. 20-30% recurrent OME → second tube (usually T-tube or long-term) + adenoidectomy (>4 years). Adult cases — Eustachian dilation also considered.

Risk group long-term follow-up: Down syndrome, cleft palate, craniofacial syndromes — lifelong OME risk — 6-monthly ENT + speech evaluation + early intervention standard.

Primary prevention: breastfeeding (≥6 months — immunity, antibody support), passive smoke avoidance (home + car strictly — strongest modifiable factor), nursery-preschool socialisation age (preferably after 18 months — more mature immunity), vaccination (Hib + pneumococcal PCV13 — reduces AOM, breaks OME chain; annual nasal influenza), allergy management (if allergic rhinitis — nasal steroid + immunotherapy review), GERD treatment (if symptomatic — PPI).

Secondary prevention (OME present): routine hearing review (annual), speech development monitoring (especially <3 years), family education (alarm features, follow-up importance), early surgical decision (long delay impacts paediatric development).

Turkish practice: Ministry of Health child examination programme includes otoscopy + age-appropriate audiometry. Preschool and school screening (especially newborn + 7 + 12 years) detects OME early. Extended Hib + PCV vaccination routine (AOM incidence decreased).

Family education messages: (1) Painless but prolonged hearing loss in child may indicate OME — don't miss; (2) Early treatment preserves speech and school performance; (3) Tube is a safe common procedure — minimal daily-life impact; (4) After tube extrusion, problem usually resolves permanently; (5) Passive smoke avoidance critical — if parents smoke, this is the first management step.

Istanbul paediatric ENT practice: private and state hospital ENT clinics experienced in paediatric OME; microscope tube placement and adenoidectomy standard. General anaesthesia performed with paediatric anaesthetists. Related reading: our patient testimonials.